Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: General Hospital of Chinese Armed Police Forces
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.

• Male or non-pregnant female; aged from 18 to 80 years old.

• Patients with non-ST-segment elevation acute coronary syndromes who were scheduled to undergoing PCI.

Exclusion Criteria:

• Any contraindication against the use of ticagrelor.

• On treatment with a P2Y12 receptor antagonist in past 30 days.

• Known allergies to aspirin or ticagrelor.

• On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).

• Known blood dyscrasia or bleeding diathesis.

• ST-segment elevation acute myocardial infarction.

• Non-ST segment elevation acute coronary syndrome with high-risk features warranting emergency coronary angiography.

• Left ventricular ejection fraction ≤30%; renal failure with creatinine 3 mg/dl; history of liver disease; an increased risk of bradycardia, and concomitant therapy with drugs interfering with CYP3A4 metabolism.